Viking Therapeutics Faces Uphill Battle in Weight-Loss Drug Market
Viking Therapeutics is under scrutiny as it attempts to carve a niche in the lucrative weight-loss drug market dominated by Eli Lilly and Novo Nordisk. The success of its candidate VK2735 hinges on navigating safety concerns and competitive disadvantages.
More from this archive